Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

EYPT

EyePoint Inc

Dec 11 • 04:00PM ET

16.10

-0.62 -3.71 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN ALNY VRTX NBIX BMRN IONS SAGE RARE AGIO BLUE

| Held by: VTI IWM VXF IWN PINK SCHA VTWO DWAS VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-2.99	Insider Own	13.79%	Shs Outstand	82.79M	Perf Week	-3.71%
Market Cap	1.33B	Forward P/E	-	EPS next Y	-2.87	Insider Trans	-0.63%	Shs Float	71.37M	Perf Month	38.26%
Enterprise Value	1.15B	PEG	-	EPS next Q	-0.75	Inst Own	74.69%	Short Float	11.04%	Perf Quarter	20.60%
Income	-205.75M	P/S	31.48	EPS this Y	-30.73%	Inst Trans	3.37%	Short Ratio	6.13	Perf Half Y	81.72%
Sales	42.34M	P/B	5.60	EPS next Y	5.46%	ROA	-74.47%	Short Interest	7.88M	Perf YTD	116.11%
Book/sh	2.88	P/C	6.53	EPS next 5Y	-4.04%	ROE	-98.23%	52W High	19.11 -15.75%	Perf Year	81.92%
Cash/sh	2.46	P/FCF	-	EPS past 3/5Y	-4.60% 15.65%	ROIC	-92.90%	52W Low	3.91 311.76%	Perf 3Y	412.74%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	5.42% 16.27%	Gross Margin	92.81%	Volatility	6.57% 7.28%	Perf 5Y	210.87%
Dividend TTM	-	EV/Sales	27.21	EPS Y/Y TTM	-49.03%	Oper. Margin	-515.65%	ATR (14)	1.02	Perf 10Y	-58.40%
Dividend Ex-Date	-	Quick Ratio	7.11	Sales Y/Y TTM	-7.38%	Profit Margin	-485.95%	RSI (14)	59.87	Recom	1.08
Dividend Gr. 3/5Y	- -	Current Ratio	7.18	EPS Q/Q	-57.88%	SMA20	9.08%	Beta	1.66	Target Price	35.50
Payout	-	Debt/Eq	0.12	Sales Q/Q	-90.82%	SMA50	20.98%	Rel Volume	0.86	Prev Close	16.72
Employees	165	LT Debt/Eq	0.11	Earnings	Nov 05 BMO	SMA200	61.78%	Avg Volume	1.29M	Price	16.10
IPO	Jan 27, 2005	Option/Short	Yes / Yes	EPS/Sales Surpr.	-10.49% -72.32%	Trades		Volume	1,108,073	Change	-3.71%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-17-25	Initiated	RBC Capital Mkts	Outperform	$28
Jan-07-25	Initiated	Citigroup	Buy	$33
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-28-24	Initiated	Jefferies	Buy	$15
Jan-22-24	Initiated	JP Morgan	Overweight	$35
Nov-02-23	Initiated	Mizuho	Buy	$20
Apr-21-23	Initiated	Robert W. Baird	Outperform	$33
Jul-07-22	Initiated	Chardan Capital Markets	Buy	$21
Mar-01-21	Initiated	Cowen	Outperform	$25
Jan-28-21	Initiated	Cantor Fitzgerald	Overweight	$22
Apr-06-20	Downgrade	B. Riley FBR	Buy → Neutral	$4 → $1
Nov-04-19	Resumed	Laidlaw	Buy	$5
Sep-12-19	Initiated	Guggenheim	Buy

Show Previous Ratings

Nov-19-25 07:00AM	EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration (GlobeNewswire)
Nov-17-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +13.43%
Nov-07-25 04:00AM	EyePoint Pharmaceuticals Inc (EYPT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Nov-05-25 08:15AM	EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -11.10%
07:22AM	EyePoint Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Loading…
07:00AM	EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Nov-04-25 08:06AM	EyePoint Pharmaceuticals Inc (EYPT) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-03-25 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Oct-29-25 07:00AM	EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025 (GlobeNewswire)
Oct-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-14-25 10:43PM	EyePoint Announces Pricing of Public Offering (GlobeNewswire) -10.87%
04:35PM	EyePoint Announces Proposed Public Offering of Common Stock (GlobeNewswire)
04:01PM	EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU in Diabetic Macular Edema (GlobeNewswire)
Sep-25-25 09:29AM	Nurix Therapeutics (NRIX) Soars 5.6%: Is Further Upside Left in the Stock? (Zacks) -6.32%
Sep-23-25 01:13PM	Biotech Stocks Rally. 3 Favorite Plays From the Charts. (Barrons.com)
07:00AM	Loading…
Sep-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-26-25 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Aug-18-25 04:01PM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-06-25 08:30AM	EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:30AM	EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (GlobeNewswire)
07:26AM	EyePoint Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Aug-05-25 10:08AM	EyePoint Pharmaceuticals Inc (EYPT) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com) +8.25%
Jul-30-25 06:00PM	Guardant Health (GH) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:00AM	EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire)
05:57AM	Enrolment concludes in EyePoints Phase III programme of Duravyu for wet AMD (Clinical Trials Arena)
Jul-29-25 07:00AM	EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration (GlobeNewswire)
Jul-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-16-25 07:00AM	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-25 11:54AM	Breakout Momentum Plays You May Not Know About (MarketBeat) +8.36%
04:01PM	Loading…
May-28-25 04:01PM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire) +18.12%
May-27-25 07:00AM	EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU for Treatment of Wet Age-Related Macular Degeneration (GlobeNewswire)
May-16-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +7.17%
May-13-25 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
May-07-25 02:49PM	Eyepoint projects DURAVYU Phase 3 enrollment completion by H2 2025 amid strong clinical trial momentum (Seeking Alpha)
02:49PM	EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:25AM	EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:22AM	EyePoint Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Apr-30-25 07:00AM	EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025 (GlobeNewswire)
Apr-16-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-27-25 07:00AM	EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference (GlobeNewswire)
Mar-17-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-06-25 02:14AM	Q4 2024 EyePoint Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:06AM	EyePoint Pharmaceuticals Inc (EYPT) Q4 2024 Earnings Call Highlights: Navigating Challenges ... (GuruFocus.com)
Mar-05-25 09:30AM	EyePoint Pharmaceuticals (EYPT) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks) +8.22%
08:25AM	EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:34AM	EyePoint Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Mar-04-25 07:17AM	Earnings To Watch: EyePoint Pharmaceuticals Inc (EYPT) Reports Q4 2024 Result (GuruFocus.com) +6.29%
07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Feb-26-25 07:00AM	EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025 (GlobeNewswire)
Feb-25-25 07:00AM	EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-17-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-05-25 07:00AM	EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU for Diabetic Macular Edema Meeting Primary and Secondary Endpoints (GlobeNewswire)
Jan-30-25 07:00AM	EyePoint to Present at Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-16-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -5.46%
Jan-13-25 07:00AM	EyePoint Provides Company Update and Anticipated Development Milestones for 2025 (GlobeNewswire) -7.07%
Jan-08-25 07:00AM	EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors (GlobeNewswire)
Dec-17-24 07:25AM	EyePoint reports inducement grants under NASDAQ listing rule (TipRanks) +5.39%
07:00AM	EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-05-24 07:06AM	EyePoint doses first patient in second Phase 3 LUCIA clinical trial (TipRanks)
Dec-04-24 07:00AM	EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU for the Treatment of Wet Age-Related Macular Degeneration (GlobeNewswire)
Nov-18-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -6.43%
Nov-13-24 09:55AM	Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High? (Zacks)
Nov-12-24 06:45AM	EyePoint price target lowered to $33 from $38 at Baird (TipRanks) -7.42%
Nov-07-24 08:35AM	EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:37AM	EyePoint Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Nov-04-24 07:00AM	EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Oct-31-24 04:00PM	EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares (GlobeNewswire)
Oct-29-24 09:47PM	EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering (GlobeNewswire)
04:49AM	EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock? (Zacks)
Oct-28-24 05:14PM	EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire) +27.58%
12:16PM	EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss (Benzinga)
07:00AM	EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU for Diabetic Macular Edema (GlobeNewswire)
Oct-24-24 07:00AM	EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration (GlobeNewswire)
Oct-23-24 09:20AM	ANI Pharmaceuticals price target raised to $62 from $60 at Truist (TipRanks) -7.35%
Oct-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +14.17%
Sep-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-04-24 07:00AM	EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors (GlobeNewswire)
Aug-27-24 07:00AM	EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Aug-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-08-24 07:00AM	EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire) +5.90%
Aug-07-24 08:15AM	EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:09AM	EyePoint Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Jul-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-15-24 08:00AM	Milestone Pharmaceuticals Refreshes Board of Directors (GlobeNewswire)
Jun-26-24 08:00AM	EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024 (GlobeNewswire)
08:00AM	EyePoint Pharmaceuticals to Highlight DURAVYU (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024 (GlobeNewswire)
Jun-18-24 07:00AM	EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024 (GlobeNewswire)
Jun-17-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-05-24 07:00AM	EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire) +6.18%
02:35AM	Insider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT) (GuruFocus.com)
May-17-24 02:34AM	Insider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT) (GuruFocus.com) -5.43%
May-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
May-10-24 02:34PM	EyePoint Pharmaceuticals Q1 2024 Earnings: Revenue Surpasses Estimates Despite Challenges (GuruFocus.com)

EyePoint Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cormorant Asset Management, LP	Former 10% Owner	Dec 04 '25	Sale	15.70	60,000	942,240	8,265,000	Dec 08 04:03 PM
Lurker Nancy	Director	Dec 04 '25	Sale	15.11	9,300	140,477	206,547	Dec 05 04:06 PM
Lurker Nancy	Officer	Dec 04 '25	Proposed Sale	15.11	9,300	140,477		Dec 04 10:24 AM
Lurker Nancy	Director	Nov 28 '25	Sale	14.95	500	7,475	215,847	Dec 01 04:09 PM
Lurker Nancy	Director	Nov 26 '25	Sale	14.95	200	2,990	216,347	Dec 01 04:09 PM
Lurker Nancy	Officer	Nov 28 '25	Proposed Sale	14.95	500	7,475		Nov 28 01:23 PM
Lurker Nancy	Officer	Nov 26 '25	Proposed Sale	14.95	200	2,990		Nov 26 04:09 PM
Ribeiro Ramiro	Chief Medical Officer	Nov 11 '25	Sale	11.61	2,722	31,602	0	Nov 12 04:03 PM
Ramiro Ribeiro	Officer	Nov 11 '25	Proposed Sale	11.35	2,722	30,895		Nov 12 06:55 AM
Zaderej Karen L.	Director	Jul 11 '25	Option Exercise	0.00	2,000	0	38,500	Jul 11 04:07 PM
Lurker Nancy	Director	Jul 10 '25	Option Exercise	0.00	11,111	0	216,547	Jul 11 04:06 PM
Duker Jay S.	President and CEO	Jul 10 '25	Option Exercise	0.00	16,667	0	17,653	Jul 11 04:06 PM
Elston George	Chief Financial Officer	May 25 '25	Option Exercise	0.00	7,500	0	83,050	May 27 04:08 PM
Zaderej Karen L.	Director	May 19 '25	Buy	5.99	5,000	29,950	36,500	May 19 04:06 PM
Zaderej Karen L.	Director	May 16 '25	Buy	5.81	5,000	29,050	31,500	May 19 04:06 PM
Zaderej Karen L.	Director	May 15 '25	Buy	5.47	5,000	27,350	26,500	May 15 04:06 PM
Zaderej Karen L.	Director	May 14 '25	Buy	5.42	5,000	27,100	21,500	May 15 04:06 PM
Elston George	Chief Financial Officer	Feb 09 '25	Option Exercise	0.00	5,834	0	75,550	Feb 11 06:19 PM
Lurker Nancy	Director	Feb 09 '25	Option Exercise	0.00	20,000	0	205,436	Feb 11 06:19 PM
Duker Jay S.	President and CEO	Feb 09 '25	Option Exercise	0.00	7,000	0	79,706	Feb 11 06:19 PM
Elston George	Chief Financial Officer	Jan 06 '25	Option Exercise	0.00	15,285	0	73,374	Jan 07 04:04 PM
Elston George	Chief Financial Officer	Jan 05 '25	Option Exercise	0.00	15,000	0	63,356	Jan 07 04:04 PM
Lurker Nancy	Director	Jan 06 '25	Option Exercise	0.00	75,134	0	185,436	Jan 07 04:04 PM
Lurker Nancy	Director	Jan 05 '25	Option Exercise	0.00	12,667	0	110,302	Jan 07 04:04 PM
Landis John B.	Director	Jan 05 '25	Option Exercise	0.00	10,000	0	21,400	Jan 07 04:04 PM
Duker Jay S.	President and CEO	Jan 06 '25	Option Exercise	0.00	20,794	0	78,814	Jan 07 04:03 PM
Duker Jay S.	President and CEO	Jan 05 '25	Option Exercise	0.00	30,000	0	68,027	Jan 07 04:03 PM

Open in Screener

OKUR

OnKure Therapeutics Inc

Dec 11 • 04:00PM ET

3.23

-0.24 -6.92 %

Healthcare • Biotechnology • USA • NASD

OKUR OnKure Therapeutics Inc daily Stock Chart

Peers: AXSM AKRO IDYA RNA FGEN MLTX ARCT PRLD PTGX CMRX

| Held by: VTI VXF IBB IWC IBBQ BIB

Index	-	P/E	-	EPS (ttm)	-6.17	Insider Own	40.31%	Shs Outstand	12.86M	Perf Week	22.81%
Market Cap	43.76M	Forward P/E	-	EPS next Y	-3.73	Insider Trans	-0.01%	Shs Float	8.09M	Perf Month	1.89%
Enterprise Value	-25.88M	PEG	-	EPS next Q	-1.15	Inst Own	50.34%	Short Float	0.51%	Perf Quarter	31.84%
Income	-81.21M	P/S	-	EPS this Y	70.16%	Inst Trans	-6.97%	Short Ratio	0.31	Perf Half Y	13.33%
Sales	0.00M	P/B	0.66	EPS next Y	18.31%	ROA	-107.93%	Short Interest	0.04M	Perf YTD	-62.44%
Book/sh	4.90	P/C	0.62	EPS next 5Y	41.03%	ROE	-115.64%	52W High	13.73 -76.47%	Perf Year	-78.47%
Cash/sh	5.19	P/FCF	-	EPS past 3/5Y	43.53% 4.41%	ROIC	-122.03%	52W Low	1.70 90.00%	Perf 3Y	-84.01%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	13.73% 10.28%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	46.20%	Oper. Margin	-	ATR (14)	0.30	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.45	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	55.60	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	11.45	EPS Q/Q	-274.33%	SMA20	9.51%	Beta	0.47	Target Price	27.00
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	7.18%	Rel Volume	1.00	Prev Close	3.47
Employees	46	LT Debt/Eq	0.00	Earnings	Nov 06 AMC	SMA200	10.19%	Avg Volume	131.52K	Price	3.23
IPO	Apr 09, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	9.02% -	Trades		Volume	131,269	Change	-6.92%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-30-25	Initiated	Evercore ISI	Outperform
Dec-05-24	Initiated	Leerink Partners	Outperform	$33
Oct-10-24	Initiated	Oppenheimer	Outperform	$35
Dec-15-23	Downgrade	Leerink Partners	Outperform → Market Perform
Dec-15-23	Downgrade	Jefferies	Buy → Hold
Dec-15-23	Downgrade	H.C. Wainwright	Buy → Neutral	$30 → $1.50
Dec-14-23	Downgrade	William Blair	Outperform → Mkt Perform
Dec-14-23	Downgrade	Robert W. Baird	Outperform → Neutral	$28 → $3
Dec-14-23	Downgrade	Piper Sandler	Overweight → Neutral	$25 → $4
Dec-14-23	Downgrade	Ladenburg Thalmann	Buy → Neutral
Dec-14-23	Downgrade	BofA Securities	Buy → Underperform	$23 → $1.45
Nov-15-23	Initiated	William Blair	Outperform	$35.55
Aug-28-23	Initiated	H.C. Wainwright	Buy	$30
Jul-03-23	Initiated	BofA Securities	Buy
Sep-19-22	Resumed	H.C. Wainwright	Buy	$31
Jan-27-22	Initiated	Robert W. Baird	Outperform	$28
Dec-21-21	Initiated	H.C. Wainwright	Buy	$28
Nov-22-21	Initiated	Ladenburg Thalmann	Buy	$45
May-04-21	Initiated	SVB Leerink	Outperform	$25
May-04-21	Initiated	Piper Sandler	Overweight	$45

Show Previous Ratings

Nov-06-25 04:03PM	OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire) +5.33% -6.96%
Nov-04-25 04:05PM	OnKure Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.20%
Aug-12-25 04:05PM	OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire) +20.00%
May-06-25 07:30AM	OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire) -11.16%
Mar-10-25 04:05PM	OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
08:00AM	Loading…
Mar-04-25 08:00AM	OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences (GlobeNewswire) +7.45%
Dec-10-24 07:00AM	OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 (GlobeNewswire) -8.47%
Nov-25-24 05:31PM	OnKure Announces New Date for Upcoming Investor Call (GlobeNewswire)
Nov-05-24 04:05PM	OnKure to Present at the Stifel 2024 Healthcare Conference (GlobeNewswire) +7.90%
Nov-01-24 05:30PM	OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire) -6.91%
Oct-07-24 04:32AM	OnKure and Reneo Pharmaceuticals complete merger (Pharmaceutical Technology)
Oct-04-24 04:57PM	OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million (GlobeNewswire) +5.20%
Oct-02-24 08:20PM	Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure (GlobeNewswire)
Aug-13-24 07:35AM	Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results (GlobeNewswire)
May-16-24 10:01AM	Reneo Pharmaceuticals Insider Bought Shares Worth $639,578, According to a Recent SEC Filing (MT Newswires)
08:25AM	Loading…
May-13-24 08:25AM	Reneo Pharmaceuticals to Merge With OnKure in All-Stock Deal -- Reneo Shares Rise (MT Newswires) -12.15%
07:35AM	Reneo Pharmaceuticals and OnKure Announce Proposed Merger (GlobeNewswire)
May-07-24 01:53PM	RPHM Stock Earnings: Reneo Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
07:35AM	Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results (GlobeNewswire)
Mar-28-24 12:53PM	RPHM Stock Earnings: Reneo Pharmaceuticals Misses EPS for Q4 2023 (InvestorPlace)
07:35AM	Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update (GlobeNewswire)
Mar-25-24 07:00AM	Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors (GlobeNewswire)
Dec-21-23 04:13PM	These Stocks under $10 Are Poised To Explode (Insider Monkey)
Dec-15-23 10:19AM	Reneo (RPHM) Plummets 83% on Failure of Metabolic Disorder Study (Zacks) +5.97%
Dec-14-23 12:35PM	Why Is Genetic Disease Focused Reneo Pharmaceuticals Stock Plummeting Today? (Benzinga) -82.71%
09:05AM	Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM) (GlobeNewswire)
Nov-13-23 05:04PM	Reneo Pharmaceuticals Inc (RPHM) Reports Q3 2023 Financial Results (GuruFocus.com)
07:35AM	Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-02-23 07:50AM	Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-25-23 07:50AM	Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings (GlobeNewswire)
01:22PM	Loading…
Oct-20-23 01:22PM	12 Best Performing Biotech Stocks in 2023 (Insider Monkey) -5.76%
Oct-09-23 07:50AM	Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM) (GlobeNewswire)
Oct-06-23 08:30AM	Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit (GlobeNewswire) +11.47%
Aug-29-23 07:35AM	Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.30%
Aug-10-23 07:35AM	Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results (GlobeNewswire)
07:31AM	Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) stock price dropped 10% last week; private equity firms would not be happy (Simply Wall St.)
Jul-27-23 11:19AM	Bank of America Says These 2 Stocks Could Double Your Money Heres Why They Could Rally (TipRanks) +17.59%
Jun-30-23 08:25AM	Reneo Pharmaceuticals to Participate in SVB Securities Therapeutics Forum (GlobeNewswire)
Jun-26-23 08:25AM	Reneo Pharmaceuticals Added to Russell 2000® and Russell 3000® Indices (GlobeNewswire)
Jun-15-23 12:44PM	Reneo Pharmaceuticals Announces Presentation and Posters at Mitochondrial Medicine Symposium 2023 (GlobeNewswire)
May-31-23 10:38AM	Update -- Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference (GlobeNewswire)
08:00AM	Reneo Pharmaceuticals to Participate at the Jefferies Healthcare Conference (GlobeNewswire)
May-21-23 07:42PM	Insiders Pour $1 Million Each Into These 2 Strong Buy Stocks Heres Why Wall Street Thinks They Could Double (or More) (TipRanks)
May-12-23 06:00PM	MP Materials, Pitney Bowes See Activist Investor Action (Barrons.com)
May-11-23 07:45AM	Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results (GlobeNewswire) +6.02%
May-03-23 11:36PM	Reneo Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
04:01PM	Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Mar-27-23 07:30AM	Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-14-23 07:30AM	Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial Myopathies (GlobeNewswire)
Mar-09-23 08:00AM	Reneo Pharmaceuticals to Present Preclinical Mavodelpar (REN001) Data at the Society for Inherited Metabolic Disorders Annual Meeting 2023 (GlobeNewswire)
Mar-03-23 06:07AM	Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) largest shareholders are private equity firms who were rewarded as market cap surged US$33m last week (Simply Wall St.)
Feb-02-23 07:35AM	Reneo Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-31-23 07:35AM	Reneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD) (GlobeNewswire)
Dec-04-22 07:12AM	Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Nov-08-22 07:35AM	Reneo Pharmaceuticals Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-03-22 08:00AM	Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences (GlobeNewswire)
Sep-14-22 06:02AM	Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) biggest owners are private equity firms who got richer after stock soared 25% last week (Simply Wall St.) +8.24%
Sep-06-22 08:35AM	Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-29-22 07:35AM	Reneo Pharmaceuticals Announces Poster Presentations at the International Network for Fatty Acid Oxidation Research and Management Annual Meeting (GlobeNewswire)
Aug-09-22 08:00AM	Reneo Pharmaceuticals Reports Second Quarter 2022 Financial Results (GlobeNewswire) -5.26%
Aug-04-22 09:10AM	Insiders who bought in the last 12 months lose an additional US$83k as Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) drops to US$57m (Simply Wall St.) +14.89%
Aug-02-22 07:30AM	Reneo Pharmaceuticals Appoints Roshawn Blunt to its Board of Directors (GlobeNewswire) -15.92%
Jul-26-22 09:52AM	Reneo Pharmaceuticals Says Metabolic Disorder Program To Enter Next Stage Of Development (Benzinga)
07:30AM	Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates (GlobeNewswire)
Jul-11-22 08:00AM	Reneo Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.84%
Jun-30-22 08:00AM	Reneo Pharmaceuticals to Present Data from Phase 1 REN001 Limb Immobilization Study at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022) (GlobeNewswire) +13.73%
Jun-20-22 08:33AM	Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Invest In Growth? (Simply Wall St.)
May-10-22 04:05PM	Reneo Pharmaceuticals Reports First Quarter 2022 Financial Results (GlobeNewswire) +9.09%
Mar-23-22 04:05PM	Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-07-22 08:30AM	Reneo Pharmaceuticals Announces Senior Leadership Promotions (GlobeNewswire)
Feb-02-22 08:00AM	Reneo Pharmaceuticals to Participate in SVB Leerink Virtual Global Healthcare Conference (GlobeNewswire) -8.93%
Jan-24-22 08:00AM	Reneo Pharmaceuticals Announces Changes to its Board of Directors (GlobeNewswire)
Jan-10-22 11:55AM	We're Not Very Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate (Simply Wall St.)
Dec-22-21 11:04AM	3 Strong Buy Stocks Under $10 With Triple-Digit Upside Potential (TipRanks) +15.28%
Nov-11-21 04:05PM	Reneo Pharmaceuticals Reports Third Quarter 2021 Financial Results (GlobeNewswire) +9.08% +5.23%
Nov-01-21 04:05PM	Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences (GlobeNewswire) +6.71%
Oct-14-21 08:00AM	Reneo Pharmaceuticals Announces Notice of Allowance for Patent Application on REN001 (GlobeNewswire)
Oct-11-21 02:35PM	Here's What Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) Shareholder Ownership Structure Looks Like (Simply Wall St.)
08:00AM	Reneo Pharmaceuticals Appoints Ashley Hall as Chief Development Officer (GlobeNewswire)
Sep-28-21 08:26AM	Reneo Pharmaceuticals Hosting Key Opinion Leader Webinar on McArdle Disease and other Genetic Mitochondrial Myopathies (GlobeNewswire)
Sep-09-21 09:12AM	Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.69%
Aug-11-21 05:55AM	Reneo Pharmaceuticals Reports Second Quarter 2021 Financial Results (GlobeNewswire)
Jul-28-21 08:00AM	Reneo Pharmaceuticals Announces First Patient Dosed in the STRIDE Study (GlobeNewswire)
Jul-12-21 09:30AM	We're Not Very Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate (Simply Wall St.) +5.29%
Jul-09-21 08:00AM	Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction (GlobeNewswire)
Jul-07-21 08:00AM	Reneo Pharmaceuticals to Present at the Ladenburg Thalmann 2021 Healthcare Conference (GlobeNewswire)
Jun-29-21 08:00AM	Reneo Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices (GlobeNewswire)
May-20-21 06:00AM	Reneo Pharmaceuticals Reports First Quarter 2021 Financial Results (GlobeNewswire) +6.34%
May-19-21 06:00AM	Reneo Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference (GlobeNewswire) +5.62%
Apr-13-21 08:14AM	The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug (Benzinga)
Apr-09-21 12:32PM	Biotech Stocks: 14 Things to Know as the VECT Stock IPO and RPHM Stock IPO Begin Trading Today (InvestorPlace)
Apr-08-21 09:42PM	Reneo Pharmaceuticals Announces Pricing of Initial Public Offering (GlobeNewswire)

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Saccomano Nicholas A	President and CEO	Sep 22 '25	Sale	2.62	88	231	3,506	Sep 24 07:42 PM
Leverone Jason A.	Chief Financial Officer	Sep 22 '25	Sale	2.62	303	795	12,603	Sep 24 07:41 PM
Saccomano Nicholas A	President and CEO	Jun 23 '25	Sale	2.38	88	210	3,594	Jun 25 06:52 PM
Leverone Jason A.	Chief Financial Officer	Jun 23 '25	Sale	2.38	303	722	12,906	Jun 25 06:49 PM
Cormorant Asset Management, LP	Former 10% Owner	May 15 '25	Sale	1.85	1,813,439	3,363,023	0	May 19 05:33 PM
ACORN BIOVENTURES, L.P.	10% Owner	May 15 '25	Buy	1.85	1,129,730	2,090,000	1,129,730	May 19 04:43 PM
ACORN BIOVENTURES, L.P.	10% Owner	May 15 '25	Buy	1.85	270,270	500,000	1,709,944	May 19 04:43 PM
Cormorant Asset Management, LP	10% Owner	May 12 '25	Sale	1.99	24,300	48,236	1,813,439	May 14 04:36 PM
Saccomano Nicholas A	President and CEO	Apr 07 '25	Sale	2.67	516	1,378	3,682	Apr 08 05:32 PM
Saccomano Nicholas A	President and CEO	Apr 04 '25	Sale	3.33	358	1,191	4,198	Apr 08 05:32 PM
Leverone Jason A.	Chief Financial Officer	Apr 07 '25	Sale	2.67	1,844	4,925	13,209	Apr 08 05:30 PM
Leverone Jason A.	Chief Financial Officer	Apr 04 '25	Sale	3.33	1,278	4,253	15,053	Apr 08 05:30 PM

Open in Screener

AARD

Aardvark Therapeutics Inc

Dec 11 • 04:00PM ET

15.61

+1.63 11.66 %

Healthcare • Biotechnology • USA • NASD

AARD Aardvark Therapeutics Inc daily Stock Chart

Held by: VTI IWM VXF IWO IWN VTWO IWC SURI RSSL VTWG

Index	RUT	P/E	-	EPS (ttm)	-2.25	Insider Own	42.68%	Shs Outstand	21.75M	Perf Week	25.89%
Market Cap	339.88M	Forward P/E	-	EPS next Y	-3.62	Insider Trans	0.39%	Shs Float	12.48M	Perf Month	41.14%
Enterprise Value	214.08M	PEG	-	EPS next Q	-0.84	Inst Own	25.48%	Short Float	10.44%	Perf Quarter	81.72%
Income	-48.77M	P/S	-	EPS this Y	42.72%	Inst Trans	4.17%	Short Ratio	6.88	Perf Half Y	41.14%
Sales	0.00M	P/B	2.77	EPS next Y	-22.67%	ROA	-44.96%	Short Interest	1.30M	Perf YTD	9.08%
Book/sh	5.63	P/C	2.69	EPS next 5Y	11.14%	ROE	-48.06%	52W High	19.58 -20.28%	Perf Year	-
Cash/sh	5.80	P/FCF	-	EPS past 3/5Y	-22.31% -	ROIC	-39.82%	52W Low	4.88 219.88%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.78% 9.09%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	31.30%	Oper. Margin	-	ATR (14)	1.11	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	12.03	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	73.85	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	12.03	EPS Q/Q	-283.59%	SMA20	40.30%	Beta	-	Target Price	33.38
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	29.23%	Rel Volume	1.69	Prev Close	13.98
Employees	22	LT Debt/Eq	0.00	Earnings	Nov 13 AMC	SMA200	41.16%	Avg Volume	189.27K	Price	15.61
IPO	Feb 13, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	6.09% -	Trades		Volume	333,123	Change	11.66%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Initiated	William Blair	Outperform
Dec-03-25	Initiated	Raymond James	Strong Buy	$47
Nov-07-25	Initiated	BTIG Research	Buy	$26
Sep-29-25	Initiated	Stifel	Buy	$24
Jun-30-25	Initiated	H.C. Wainwright	Buy	$40
Mar-10-25	Initiated	RBC Capital Mkts	Outperform	$21
Mar-10-25	Initiated	Morgan Stanley	Overweight	$29
Mar-10-25	Initiated	Cantor Fitzgerald	Overweight	$50
Mar-10-25	Initiated	BofA Securities	Buy	$22

Dec-11-25 04:27PM	Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win (Investor's Business Daily) +11.66%
Dec-10-25 04:05PM	Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome (GlobeNewswire)
Nov-25-25 04:05PM	Aardvark Therapeutics to Present at Upcoming Investor Conferences in December (GlobeNewswire)
Nov-13-25 04:05PM	Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates (GlobeNewswire) -8.66%
Nov-11-25 04:05PM	Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +5.94%
09:33AM	Loading…
Nov-07-25 09:33AM	Datadog, Trade Desk upgraded: Wall Street's top analyst calls (The Fly)
Nov-04-25 12:00PM	Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025 (GlobeNewswire) -5.68%
Nov-03-25 05:55PM	Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
08:00AM	Aardvark Therapeutics to Present at Upcoming Investor Conferences in November (GlobeNewswire)
Oct-22-25 08:00AM	Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek (GlobeNewswire) -8.28%
Oct-17-25 09:27AM	Aardvark Therapeutics Expands Phase 3 HERO Trial Eligibility for ARD-101 in Prader-Willi Syndrome After FDA Protocol Alignment (Insider Monkey)
Oct-08-25 08:00AM	Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome (GlobeNewswire)
Sep-23-25 04:05PM	Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum (GlobeNewswire) +6.38%
Sep-22-25 08:01AM	MapLight lines up an IPO in bid to challenge Bristol Myers schizophrenia drug (BioPharma Dive)
Sep-10-25 09:22PM	LB Pharmaceuticals raises $285 million in US IPO (Reuters)
08:00AM	Loading…
Sep-04-25 08:00AM	Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Aug-27-25 04:10PM	Aardvark Therapeutics to Present at Upcoming Investor Conferences in September (GlobeNewswire) -5.67% -5.56%
Aug-13-25 04:10PM	Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates (GlobeNewswire) +11.55%
Aug-12-25 08:00AM	Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy (GlobeNewswire) -9.96%
Jul-18-25 08:00AM	Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) (GlobeNewswire)
Jul-15-25 07:30AM	OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company (PR Newswire)
Jul-01-25 05:31PM	Aardvark's Hunger-Suppressing Drug Promises Weight Loss Without GI Distress (Benzinga)
Jun-24-25 08:00AM	Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference (GlobeNewswire) +18.23%
Jun-03-25 09:55AM	Wall Street Analysts Think Aardvark Therapeutics, Inc. (AARD) Could Surge 180.77%: Read This Before Placing a Bet (Zacks)
May-19-25 04:10PM	Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions (GlobeNewswire) +5.46% +5.47%
May-14-25 04:10PM	Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire) -13.81%
May-07-25 04:05PM	Aardvark Therapeutics to Present at Upcoming Investor Conferences in May (GlobeNewswire)
Mar-31-25 04:10PM	Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights (GlobeNewswire) +10.39%
Mar-27-25 04:18PM	Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower (Investor's Business Daily) -5.52% -13.03%
Mar-21-25 09:20AM	Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory (SeekingAlpha) +7.95%
11:25AM	Loading…
Mar-14-25 11:25AM	Aardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last Month (Insider Monkey)
Mar-03-25 02:55PM	Aardvark Therapeutics (AARD): Among Stocks With At Least $10 Million In Insider Spending Recently (Insider Monkey)
Feb-12-25 10:38PM	Aardvark Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel, small-molecule therapeutics for the treatment of metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lee Tien-Li	Chief Executive Officer	Oct 15 '25	Option Exercise	4.24	1,229	5,211	1,544,613	Oct 16 06:14 PM
Jones Bryan	Chief Operating Officer	Oct 15 '25	Option Exercise	4.24	1,250	5,300	1,250	Oct 16 06:12 PM
Lee Tien-Li	Chief Executive Officer	Sep 15 '25	Buy	9.66	10,000	96,624	1,543,384	Sep 16 06:15 AM
VICKERS VENT GLB DEEP-TECH FND	Director	Sep 15 '25	Proposed Sale	9.02	10,360	93,413		Sep 15 04:05 PM
Lee Tien-Li	Chief Executive Officer	Sep 10 '25	Buy	7.91	9,000	71,212	1,522,384	Sep 12 08:28 PM
Lee Tien-Li	Chief Executive Officer	Sep 11 '25	Buy	7.82	6,000	46,926	1,528,384	Sep 12 08:28 PM
Lee Tien-Li	Chief Executive Officer	Sep 12 '25	Buy	8.50	5,000	42,516	1,533,384	Sep 12 08:28 PM
Sun Nelson	Chief Financial Officer	Sep 09 '25	Buy	8.07	6,000	48,440	105,484	Sep 10 05:36 PM
VICKERS VENT GLB DEEP-TECH FND	Director	Sep 02 '25	Proposed Sale	8.51	20,000	170,118		Sep 02 04:05 PM
Lee Tien-Li	Chief Executive Officer	Aug 28 '25	Option Exercise	4.24	17,209	72,966	1,513,384	Aug 29 04:05 PM
VICKERS VENT GLB DEEP-TECH FND	Director	Aug 28 '25	Proposed Sale	8.72	27,691	241,565		Aug 28 04:36 PM
Decheng Capital Global Life Sc	10% Owner	Feb 14 '25	Buy	16.00	1,250,000	20,000,000	2,958,887	Feb 19 05:44 PM
Lee Tien-Li	Chief Executive Officer	Feb 14 '25	Buy	16.00	16,542	264,672	1,496,175	Feb 19 04:35 PM
Sun Nelson	Chief Financial Officer	Feb 14 '25	Buy	16.00	10,000	160,000	99,484	Feb 19 04:30 PM
Cormorant Asset Management, LP	Former 10% Owner	Feb 14 '25	Buy	16.00	187,500	3,000,000	987,689	Feb 19 04:02 PM

Open in Screener

DRUG

Bright Minds Biosciences Inc

Dec 11 • 04:00PM ET

89.01

+4.62 5.47 %

Healthcare • Biotechnology • USA • NASD

DRUG Bright Minds Biosciences Inc daily Stock Chart

Peers: CMPS MNMD SAGE ATAI NBIX CYBN RLMD GHRS CYPH

| Held by: IWM IWO PSIL VTWO IWC VFMO VTWG OMFS RSSL IBRN

Index	RUT	P/E	-	EPS (ttm)	-0.95	Insider Own	33.72%	Shs Outstand	7.08M	Perf Week	22.77%
Market Cap	693.39M	Forward P/E	-	EPS next Y	-4.90	Insider Trans	0.00%	Shs Float	5.16M	Perf Month	50.25%
Enterprise Value	655.83M	PEG	-	EPS next Q	-0.56	Inst Own	55.87%	Short Float	5.24%	Perf Quarter	82.58%
Income	-6.38M	P/S	-	EPS this Y	-223.24%	Inst Trans	6.41%	Short Ratio	1.85	Perf Half Y	213.64%
Sales	0.00M	P/B	16.60	EPS next Y	-234.34%	ROA	-29.62%	Short Interest	0.27M	Perf YTD	147.11%
Book/sh	5.36	P/C	18.41	EPS next 5Y	-	ROE	-30.05%	52W High	88.00 1.15%	Perf Year	130.42%
Cash/sh	4.83	P/FCF	-	EPS past 3/5Y	49.96% -59.48%	ROIC	-16.77%	52W Low	23.17 284.08%	Perf 3Y	1533.21%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	13.25% 8.13%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-38.86%	Oper. Margin	-	ATR (14)	6.10	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	86.56	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	78.98	Recom	1.17
Dividend Gr. 3/5Y	- -	Current Ratio	86.56	EPS Q/Q	-1581.44%	SMA20	30.13%	Beta	-6.11	Target Price	77.40
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	41.81%	Rel Volume	0.99	Prev Close	84.39
Employees	-	LT Debt/Eq	0.00	Earnings	Aug 14 BMO	SMA200	113.20%	Avg Volume	146.04K	Price	89.01
IPO	Mar 22, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	6.78% -	Trades		Volume	142,859	Change	5.47%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-08-25	Initiated	BTIG Research	Buy	$72
May-13-25	Initiated	TD Cowen	Buy
May-07-25	Initiated	Chardan Capital Markets	Buy	$80
Jan-23-25	Initiated	Piper Sandler	Overweight	$93
Jan-10-25	Initiated	H.C. Wainwright	Buy	$85
Jan-10-25	Initiated	Cantor Fitzgerald	Overweight
Nov-26-24	Initiated	Robert W. Baird	Outperform	$75

Nov-26-25 08:55AM	Recent Price Trend in Bright Minds Biosciences Inc. (DRUG) is Your Friend, Here's Why (Zacks)
Nov-25-25 04:30PM	Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting (GlobeNewswire) +8.37%
09:55AM	Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 36.27%: Read This Before Placing a Bet (Zacks)
Nov-17-25 05:29PM	Why Bright Minds Biosciences Stock Topped the Market on Monday (Motley Fool)
06:50AM	Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS) (GlobeNewswire)
06:30AM	Loading…
Nov-06-25 06:30AM	Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH (GlobeNewswire) +7.55%
Oct-30-25 06:30PM	Bright Minds Biosciences to Present at Upcoming Conferences (GlobeNewswire)
Oct-15-25 08:50AM	Bright Minds Biosciences Inc. (DRUG) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Sep-18-25 09:55AM	Wall Street Analysts Believe Bright Minds Biosciences Inc. (DRUG) Could Rally 81.29%: Here's is How to Trade (Zacks) +12.23%
Sep-07-25 05:29PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Sep-04-25 08:30AM	Bright Minds Biosciences Announces BMB-201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model (GlobeNewswire)
Sep-02-25 09:55AM	Does Bright Minds Biosciences Inc. (DRUG) Have the Potential to Rally 114.07% as Wall Street Analysts Expect? (Zacks)
03:50AM	Bright Minds Biosciences Inc. (DRUG) Advances Phase 2 Trial for Drug-Resistant Epilepsy (Insider Monkey)
Aug-25-25 08:00AM	Bright Minds Biosciences to Present at Upcoming Conferences (GlobeNewswire) -5.14%
May-28-25 08:00AM	Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire)
08:00AM	Loading…
May-20-25 08:00AM	Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025 (GlobeNewswire)
May-13-25 08:30AM	Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101 (GlobeNewswire)
May-11-25 03:33PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
May-09-25 11:11AM	Psychedelic: Compass, GH Research, MindMed report quarterly earnings (TipRanks)
Apr-28-25 08:00AM	Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study (GlobeNewswire)
Apr-16-25 12:09PM	Bright Minds Biosciences: A Buy With A Major Catalyst In Q2 2025 (Seeking Alpha)
Mar-04-25 08:00AM	Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research (GlobeNewswire) -7.70%
Feb-24-25 06:50AM	Bright Minds Biosciences to Participate at Three Healthcare Conferences in March (GlobeNewswire)
Jan-07-25 06:50AM	Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire)
Nov-21-24 09:00AM	Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting (GlobeNewswire)
Nov-06-24 06:30AM	Bright Minds Biosciences Secures $35 Million Investment (TipRanks)
Nov-04-24 02:41PM	Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement (GlobeNewswire) +5.00%
Oct-21-24 08:30AM	Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data (GlobeNewswire)
Oct-18-24 06:50AM	Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement (GlobeNewswire) +117.56%
Oct-16-24 10:45AM	Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models (GlobeNewswire) -25.18%
09:20AM	Loading…
09:20AM	Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA Technology (GlobeNewswire)
05:57AM	Biotech stock tumbles after unexplained 1,446% gain (MarketWatch)
Oct-15-24 09:09PM	Bright Minds is Unaware of Any Material Changes (Newsfile) +1,445.78%
Oct-03-24 09:00AM	Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events (GlobeNewswire)
Sep-19-24 10:00AM	Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th (GlobeNewswire)
Sep-12-24 08:00AM	Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy (PR Newswire)
Aug-12-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
May-20-24 11:53AM	DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q2 2024 (InvestorPlace)
Dec-06-23 05:08PM	Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management (PR Newswire) +5.53%
Aug-08-23 06:50AM	Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101 (GlobeNewswire) +29.50%
Jul-20-23 06:50AM	Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101 (GlobeNewswire) -16.38%
Jul-11-23 06:50AM	Bright Minds Announces Effective Date of Share Consolidation (GlobeNewswire)
Jun-22-23 06:50AM	Bright Minds Announces Proposed Share Consolidation (GlobeNewswire) +5.33%
Apr-19-23 06:50AM	Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202 (GlobeNewswire) +26.08%
Apr-10-23 06:50AM	Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research (GlobeNewswire)
Feb-27-23 06:50AM	Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023 (GlobeNewswire) -10.54%
Feb-17-23 06:50AM	Bright Minds Biosciences Announces Non-Executive Director Appointment (GlobeNewswire)
Feb-08-23 04:05PM	Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements (GlobeNewswire) -6.58%
Jan-27-23 04:05PM	Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency (GlobeNewswire) -6.59%
Jan-09-23 04:05PM	Bright Minds Biosciences Announces Resignation of Board Member (GlobeNewswire) -7.46%
Dec-02-22 07:07PM	Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement (GlobeNewswire)
Nov-28-22 06:50AM	Bright Minds Biosciences Announces Non-Brokered Private Placement (GlobeNewswire) +10.78%
Nov-23-22 11:35AM	Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer (GlobeNewswire)
Sep-07-22 06:50AM	Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors (GlobeNewswire)
Aug-31-22 06:50AM	Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome (GlobeNewswire) -15.42%
Aug-30-22 03:35PM	Bright Minds Biosciences Announces Closing of $4 Million Unit Offering (GlobeNewswire) -23.05%
Aug-23-22 09:07PM	Bright Minds Announces Pricing of Overnight Marketed Offering of Units (GlobeNewswire) -38.43% +48.87%
Aug-22-22 07:05PM	Bright Minds Announces Overnight Marketed Offering of Units (GlobeNewswire) +72.80%
Aug-18-22 03:34PM	Bright Minds Biosciences Comments on Recent Trading Activity (GlobeNewswire) +121.43%
Jun-27-22 06:50AM	Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization (GlobeNewswire)
May-12-22 06:50AM	Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome (GlobeNewswire)
May-02-22 06:50AM	Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties (GlobeNewswire)
Apr-19-22 06:50AM	Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders (GlobeNewswire) +8.40%
Mar-14-22 06:50AM	Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial (GlobeNewswire)
Mar-08-22 07:30AM	Bright Minds Biosciences to Present at the Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire)
Jan-04-22 04:05PM	Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference (GlobeNewswire)
Dec-15-21 05:13PM	Canadian Securities Exchange's November 2021 Performance Includes Strong Listings Growth and New Financing Milestone (Newsfile) +5.88%
Dec-06-21 06:50AM	Bright Minds Biosciences to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference (GlobeNewswire)
Nov-30-21 07:30AM	Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases (GlobeNewswire) -8.35%

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in New York, NY.

Held by: VTI IWM IWN VXF SCHA FESM VTWO IWC RSSL VTWV

Index	RUT	P/E	-	EPS (ttm)	-2.11	Insider Own	37.23%	Shs Outstand	35.85M	Perf Week	21.43%
Market Cap	457.15M	Forward P/E	-	EPS next Y	-2.91	Insider Trans	-0.65%	Shs Float	22.50M	Perf Month	62.84%
Enterprise Value	178.50M	PEG	-	EPS next Q	-0.77	Inst Own	35.54%	Short Float	2.24%	Perf Quarter	165.62%
Income	-75.79M	P/S	77.22	EPS this Y	65.32%	Inst Trans	1.89%	Short Ratio	1.22	Perf Half Y	183.96%
Sales	5.92M	P/B	1.65	EPS next Y	-26.44%	ROA	-23.59%	Short Interest	0.50M	Perf YTD	120.21%
Book/sh	7.74	P/C	1.60	EPS next 5Y	22.89%	ROE	-25.64%	52W High	12.80 -0.39%	Perf Year	174.19%
Cash/sh	7.97	P/FCF	-	EPS past 3/5Y	-30.62% -	ROIC	-27.08%	52W Low	2.88 342.71%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	96.77%	Volatility	8.89% 6.53%	Perf 5Y	-
Dividend TTM	-	EV/Sales	30.15	EPS Y/Y TTM	-	Oper. Margin	-1516.29%	ATR (14)	0.70	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.87	Sales Y/Y TTM	-	Profit Margin	-1280.90%	RSI (14)	82.56	Recom	2.50
Dividend Gr. 3/5Y	- -	Current Ratio	11.87	EPS Q/Q	17.81%	SMA20	32.39%	Beta	1.64	Target Price	12.00
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	63.45%	Rel Volume	5.02	Prev Close	12.68
Employees	64	LT Debt/Eq	0.01	Earnings	Nov 06 AMC	SMA200	144.13%	Avg Volume	413.06K	Price	12.75
IPO	Sep 26, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.04% 164.18%	Trades		Volume	1,932,729	Change	0.55%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-05-25	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$12
Oct-22-25	Upgrade	Citigroup	Neutral → Buy	$10
Feb-28-25	Initiated	William Blair	Mkt Perform
Dec-10-24	Downgrade	Morgan Stanley	Overweight → Underweight	$40 → $5
Dec-09-24	Downgrade	Jefferies	Buy → Hold	$42 → $7
Dec-09-24	Downgrade	Citigroup	Buy → Neutral	$45 → $7
Oct-21-24	Initiated	Morgan Stanley	Overweight	$40
Oct-21-24	Initiated	Jefferies	Buy	$42
Oct-21-24	Initiated	Citigroup	Buy	$45

Dec-04-25 09:00AM	BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor (GlobeNewswire) +13.88%
Nov-25-25 04:30PM	BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-07-25 09:00AM	BioAge Labs to Present at Jefferies Global Healthcare Conference in London (GlobeNewswire)
Nov-06-25 04:45PM	BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-05-25 07:45AM	Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy (Motley Fool)
06:15AM	Loading…
Oct-29-25 06:15AM	Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026? (Motley Fool)
Oct-26-25 06:33PM	BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher? (Motley Fool)
Oct-23-25 07:36AM	Ventyx shares soar after study suggests cardiovascular benefits for experimental drug (BioPharma Dive) +31.40%
Aug-20-25 04:30PM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-18-25 07:36AM	BioAge commences dosing in trial of obesity treatment candidate BGE-102 (Clinical Trials Arena)
Aug-15-25 09:00AM	BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor (GlobeNewswire)
Aug-06-25 04:30PM	BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-29-25 10:23AM	BioAge (BIOA) to Analyze Over 17,000 Biobank Samples for Drug Discovery (Insider Monkey)
Jun-21-25 06:00PM	BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions (GlobeNewswire)
Jun-17-25 09:00AM	BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank (GlobeNewswire)
09:00AM	Loading…
Jun-03-25 09:00AM	BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates (GlobeNewswire)
May-30-25 09:05AM	BioAge Labs completes IND-enabling studies for BGE-102 (TipRanks)
May-29-25 11:18PM	BioAge Labs, Inc. (BIOA)'s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025 (Insider Monkey)
09:00AM	BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic (GlobeNewswire)
May-27-25 04:30PM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
May-06-25 04:30PM	BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-21-25 01:02PM	BioAge Labs, Inc. (BIOA): A Bull Case Theory (Insider Monkey)
Mar-22-25 11:00AM	Investors To Focus On PCE Price Index Print As Cintas, Lululemon To Report Earnings (SeekingAlpha)
Mar-20-25 04:30PM	BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024 (GlobeNewswire)
Mar-17-25 01:54PM	BioArctic receives Orphan Drug Designation for exidavnemab the US (PR Newswire)
Mar-04-25 05:07AM	BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman (Newsfile)
Feb-20-25 04:30PM	BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference (GlobeNewswire)
10:36AM	BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman (Newsfile)
Feb-16-25 07:18AM	BIOA COURT NEWS: BioAge Labs has been Sued for Securities Violations; Contact BFA Law by March 10 if You Lost Money (NASDAQ:BIOA) (GlobeNewswire)
Feb-14-25 05:45AM	Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire) +5.97%
08:42AM	Loading…
Feb-13-25 08:42AM	BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman (Newsfile)
Feb-07-25 05:45AM	BioAge Labs, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire)
Jan-30-25 09:01AM	BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman (Newsfile)
Jan-29-25 05:39AM	BioAge drops obesity drug; Akero, 89bio cash in on MASH data (BioPharma Dive) -6.40%
Jan-28-25 07:27PM	Kessler Topaz Meltzer & Check, LLP Encourages BioAge Labs, Inc. Investors with Losses to Contact the Firm (PR Newswire)
09:00AM	BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs (GlobeNewswire)
Jan-24-25 05:45AM	Shareholders of BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire)
Jan-22-25 03:00AM	After an obesity stumble, BioAge reconnects with its longevity pipeline (Pharma Voice)
Jan-21-25 05:45AM	Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire)
Jan-18-25 03:07AM	BIOAGE LABS (BIOA) Investors are Notified the Company has been Sued and are Urged to Contact BFA Law by March 10 (Newsfile)
Jan-06-25 09:00PM	Bragar Eagel and Squire, P.C. Is Investigating Franklin, MediaAlpha, e.l.f. Beauty, and BioAge and Encourages Investors to Contact the Firm (GlobeNewswire) -7.39%
Jan-03-25 12:51PM	BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman (PR Newswire)
Jan-02-25 09:35AM	BioAge Labs, Inc. (BIOA) Loses -67.99% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jan-01-25 05:00AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman (Newsfile)
Dec-27-24 11:32AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire) -6.46%
09:18AM	BioAge Labs, Inc. (BIOA): A Bull Case Theory (Insider Monkey)
Dec-26-24 07:23AM	Kirby McInerney LLP is Investigating Potential Shareholder Claims Against BioAge Labs, Inc. (BIOA) (Newsfile)
Dec-25-24 07:04AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman (Newsfile)
Dec-23-24 10:19AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire)
Dec-19-24 01:15PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire) +20.23%
05:46AM	BioAge and Novartis seek drug targets for ageing-related diseases (Pharmaceutical Technology)
Dec-18-24 09:00AM	BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions (GlobeNewswire)
Dec-16-24 04:20PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire)
03:00AM	3 closely watched drugs that failed in the clinic (Pharma Voice)
Dec-13-24 10:31AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman (Newsfile) -6.75%
Dec-12-24 06:34PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire)
Dec-09-24 07:51PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire) -76.85%
09:28AM	BioAge halts ongoing Phase II trial of obesity drug due to liver concerns (Clinical Trials Arena)
07:41AM	Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns (Benzinga)
Dec-07-24 06:34AM	BioAge shares tumble after decision to halt obesity drug study (BioPharma Dive)
Dec-06-24 04:35PM	BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity (GlobeNewswire) +9.36% -76.85%
Dec-05-24 04:30PM	BioAge Labs to Present at Goldman Sachs Year-Ahead Catalyst Clinic (GlobeNewswire)
Dec-04-24 04:47PM	Why BioAge Labs (BIOA) is the Best All-Time Low Stock to Buy Right Now? (Insider Monkey)
Nov-21-24 04:30PM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-12-24 11:01PM	BioAge Labs Reports Strong Q3 2024 Achievements (TipRanks) -11.78%
Nov-07-24 04:30PM	BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -10.11% +7.61%
Nov-04-24 09:00AM	BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024 (GlobeNewswire)
Oct-24-24 09:00AM	BioAge Labs to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Oct-21-24 10:53AM	Wall Street analysts initiate coverage of BioAge Labs (Investing.com) +8.26%
Oct-17-24 09:45AM	Prediction: These 2 Stocks Could Soar in 2025 (Motley Fool)
Oct-12-24 02:31PM	Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock (Motley Fool)
Oct-07-24 09:10PM	RA Capital Management, L.P. Acquires New Stake in Bioage Labs Inc (GuruFocus.com)
Oct-05-24 07:15AM	3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October (Motley Fool)
Oct-03-24 09:05AM	This IPO Biotech Stock Could Be the Next Eli Lilly (Motley Fool) +5.73%
Oct-01-24 04:30PM	BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of the Concurrent Private Placement (GlobeNewswire)
Sep-26-24 04:08PM	BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rises On Upsized IPO (Investor's Business Daily)
02:36PM	A weight loss drug developer's stock soars after a $198 million IPO (Quartz)
08:25AM	BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq (FastCompany)
Sep-25-24 08:00PM	BioAge Labs Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)
04:13PM	BioAge prices $198M IPO, validating pivot to obesity drug research (BioPharma Dive)
11:27AM	A weight loss drug maker is aiming for a big IPO (Quartz)
Jan-01-01 12:00AM	BioAge Labs, Inc. (BIOA)'s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025 (Insider Monkey)

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RUBIN PAUL D	Chief Medical Officer	Dec 09 '25	Option Exercise	6.57	18,000	118,260	18,000	Dec 11 04:21 PM
RUBIN PAUL D	Chief Medical Officer	Dec 09 '25	Sale	12.00	18,000	216,000	0	Dec 11 04:21 PM
RUBIN PAUL D	Officer	Dec 09 '25	Proposed Sale	12.00	18,000	216,000		Dec 09 11:23 AM
RUBIN PAUL D	Chief Medical Officer	Dec 04 '25	Option Exercise	4.11	68,897	283,167	68,897	Dec 05 06:20 PM
RUBIN PAUL D	Chief Medical Officer	Dec 04 '25	Sale	10.19	68,897	701,909	0	Dec 05 06:20 PM
RUBIN PAUL D	Officer	Dec 04 '25	Proposed Sale	10.19	68,897	701,912		Dec 04 04:30 PM

Open in Screener

CRBP

Corbus Pharmaceuticals Holdings Inc

Dec 11 • 04:00PM ET

9.68

-0.58 -5.65 %

Healthcare • Biotechnology • USA • NASD

CRBP Corbus Pharmaceuticals Holdings Inc daily Stock Chart

Peers: VRTX BMRN GILD NBIX INCY EXEL FOLD NKTR PBYI XOMA

| Held by: VTI VXF IWC DFAS AVSC DFAC DFSU MSSM RFLR

Index	-	P/E	-	EPS (ttm)	-5.51	Insider Own	7.79%	Shs Outstand	17.55M	Perf Week	-9.45%
Market Cap	169.91M	Forward P/E	-	EPS next Y	-4.99	Insider Trans	-2.96%	Shs Float	16.19M	Perf Month	-7.10%
Enterprise Value	67.69M	PEG	-	EPS next Q	-1.54	Inst Own	49.18%	Short Float	6.29%	Perf Quarter	1.89%
Income	-67.51M	P/S	-	EPS this Y	-82.37%	Inst Trans	-1.17%	Short Ratio	2.28	Perf Half Y	5.56%
Sales	0.00M	P/B	1.32	EPS next Y	25.70%	ROA	-49.34%	Short Interest	1.02M	Perf YTD	-17.97%
Book/sh	7.35	P/C	1.63	EPS next 5Y	-13.52%	ROE	-55.65%	52W High	20.56 -52.92%	Perf Year	-36.48%
Cash/sh	5.94	P/FCF	-	EPS past 3/5Y	30.83% 35.71%	ROIC	-73.02%	52W Low	4.64 108.62%	Perf 3Y	161.69%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.68% 7.24%	Perf 5Y	-77.28%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-17.43%	Oper. Margin	-	ATR (14)	0.90	Perf 10Y	-80.91%
Dividend Ex-Date	-	Quick Ratio	6.31	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	33.79	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.31	EPS Q/Q	-65.32%	SMA20	-12.08%	Beta	2.75	Target Price	42.05
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	-27.43%	Rel Volume	13.64	Prev Close	10.26
Employees	28	LT Debt/Eq	0.00	Earnings	Nov 12 BMO	SMA200	2.55%	Avg Volume	445.41K	Price	9.68
IPO	Oct 27, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-14.69% -	Trades		Volume	5,026,876	Change	-5.65%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-30-25	Resumed	B. Riley Securities	Buy	$28
Feb-28-25	Initiated	William Blair	Outperform
Dec-02-24	Initiated	Piper Sandler	Overweight
Jul-30-24	Initiated	Wedbush	Outperform	$85
Jul-22-24	Resumed	H.C. Wainwright	Buy	$80
Jun-26-24	Initiated	B. Riley Securities	Buy	$85
Jun-03-24	Reiterated	Oppenheimer	Outperform	$60 → $80
May-13-24	Initiated	RBC Capital Mkts	Outperform	$77
Mar-06-24	Upgrade	Jefferies	Hold → Buy	$4 → $46
Sep-08-20	Downgrade	ROTH Capital	Buy → Neutral	$40 → $3
Sep-08-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-08-20	Downgrade	Jefferies	Buy → Hold	$18 → $2.50
Sep-08-20	Downgrade	BTIG Research	Buy → Neutral
Jul-07-20	Initiated	ROTH Capital	Buy	$40
Jun-17-20	Initiated	BTIG Research	Buy	$22
Mar-26-20	Initiated	Nomura	Buy	$12
Apr-05-19	Initiated	Jefferies	Buy
Mar-20-19	Initiated	Oppenheimer	Outperform	$28
Jan-11-19	Reiterated	Cantor Fitzgerald	Overweight	$36 → $38
Dec-26-18	Initiated	H.C. Wainwright	Buy	$24

Show Previous Ratings

Dec-11-25 11:16AM	2 Pharma Stocks Pop on Strong Obesity Drug Trial Results (Schaeffer's Research) -5.65%
07:00AM	Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss (GlobeNewswire)
Dec-10-25 04:01PM	Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025 (GlobeNewswire)
Nov-12-25 08:09AM	Corbus Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance) +7.39%
08:00AM	Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
08:00AM	Loading…
Nov-06-25 08:00AM	Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-31-25 02:40AM	Corbus Pharmaceuticals Announces Pricing of Public Offering (GlobeNewswire) -26.09%
Oct-30-25 04:31PM	Corbus Pharmaceuticals Announces Proposed Public Offering (GlobeNewswire)
Oct-18-25 03:00AM	Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25 (GlobeNewswire)
Oct-14-25 08:00AM	Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025 (GlobeNewswire)
Oct-07-25 08:00AM	Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium (GlobeNewswire)
Sep-22-25 08:00AM	Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025 (GlobeNewswire)
Sep-16-25 08:00AM	FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma (GlobeNewswire) +9.61%
Aug-08-25 10:15AM	Can Cannabis Stocks Reverse Their Prolonged Downtrend? (Zacks) -6.33%
Aug-05-25 08:11AM	Corbus Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Loading…
08:00AM	Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Jul-30-25 08:00AM	Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress (GlobeNewswire)
Jun-30-25 08:00AM	Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity (GlobeNewswire) -6.76%
Jun-25-25 08:00AM	Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab (GlobeNewswire) +8.92%
Jun-24-25 04:05PM	Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium (GlobeNewswire)
May-23-25 11:13AM	3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies (Zacks)
May-22-25 08:00AM	Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-19-25 08:00AM	Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair (GlobeNewswire) +5.72%
May-16-25 07:48AM	Is Small-Cap Corbus Pharma a Worthy Cannabis Investment? (Zacks)
May-08-25 08:00AM	Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference (GlobeNewswire) +8.48%
07:20AM	Cannabis Stock Tilray Brands Loses 19% in a Month: Time to Sell or Hold? (Zacks)
May-06-25 08:08AM	Corbus Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance) -15.77%
08:00AM	Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-29-25 08:14AM	3 Unconventional Cannabis Stocks to Watch in 2025 (Zacks)
Apr-18-25 09:55AM	Wall Street Analysts See a 764.18% Upside in Corbus Pharmaceuticals (CRBP): Can the Stock Really Move This High? (Zacks)
08:00AM	Loading…
Mar-28-25 08:00AM	Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity (GlobeNewswire)
Mar-20-25 09:35AM	After Plunging -22.69% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP) (Zacks)
Mar-19-25 09:35AM	After Plunging -22.9% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP) (Zacks)
Mar-13-25 12:00PM	Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's What You Should Know (Zacks) -7.09%
Mar-11-25 08:17AM	Corbus Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Feb-25-25 08:00AM	Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-14-25 01:17PM	Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate (Benzinga) -10.23%
07:30AM	CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025 (GlobeNewswire)
Feb-11-25 07:30AM	Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU (GlobeNewswire) -10.22%
Jan-28-25 08:00AM	Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-08-25 08:00AM	Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025 (GlobeNewswire)
Jan-06-25 08:00AM	Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-09-24 07:00AM	Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors (GlobeNewswire)
Dec-04-24 12:31PM	Why Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Dec-03-24 07:00AM	FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer (GlobeNewswire) -6.11%
Nov-26-24 06:54AM	Corbus Pharmaceuticals Holdings, Inc. (CRBP): An Oversold Healthcare Stock to Invest In Now (Insider Monkey)
Nov-21-24 08:00AM	Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference (GlobeNewswire)
Nov-12-24 08:00AM	Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-07-24 07:28AM	Corbus Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Nov-04-24 04:10PM	Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk Beat (Investor's Business Daily) +8.22%
07:00AM	Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024 (GlobeNewswire)
Oct-29-24 08:00AM	Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference (GlobeNewswire)
Oct-16-24 08:00AM	Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701) (GlobeNewswire)
Oct-15-24 07:02PM	Millennium Management LLC Adjusts Stake in Corbus Pharmaceuticals (GuruFocus.com)
Oct-11-24 07:02PM	Octagon Capital Advisors LP Increases Stake in Corbus Pharmaceuticals Holdings Inc (GuruFocus.com)
Oct-03-24 05:07AM	Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) the Best Russell 2000 Stock to Buy According to Analysts? (Insider Monkey)
Sep-26-24 08:00AM	Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit (GlobeNewswire)
Sep-24-24 09:41PM	Cormorant Asset Management's Strategic Acquisition in Corbus Pharmaceuticals (GuruFocus.com) +16.41%
Sep-20-24 03:18PM	Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players (Benzinga) -62.26%
Sep-12-24 07:59AM	Transforming Cancer Therapy Stocks to Watch In The Oncology Sector (News Direct)
Sep-05-24 08:00AM	Corbus Pharmaceuticals to Present at the 2024 Cantor Global Health Conference (GlobeNewswire) -8.32%
Sep-04-24 07:29PM	Corbus Pharmaceuticals Holdings, Inc. (CRBP): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-27-24 08:03PM	Corbus Pharmaceuticals Holdings, Inc. (CRBP): One of Oppenheimers Top Stock Picks For the Next 12 Months (Insider Monkey)
Aug-26-24 09:55AM	Wall Street Analysts Think Corbus Pharmaceuticals (CRBP) Could Surge 43.82%: Read This Before Placing a Bet (Zacks)
Aug-21-24 05:00AM	The Future of Medicine: Key Biotech Stocks to Watch (News Direct) +7.45%
Aug-20-24 08:00AM	Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung (GlobeNewswire)
Aug-09-24 12:00PM	Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's Why (Zacks) +5.54%
09:55AM	Wall Street Analysts Believe Corbus Pharmaceuticals (CRBP) Could Rally 54.24%: Here's is How to Trade (Zacks)
Aug-06-24 08:08AM	Corbus Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Jul-30-24 08:50AM	Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August (GlobeNewswire) +7.13%
Jul-01-24 11:13AM	Google DeepMind CEO: 'This Is the Next $100 Billion AI Business' (InvestorPlace) +9.17%
Jun-30-24 10:13AM	Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn't Discovered Yet (InvestorPlace)
Jun-01-24 10:00AM	SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024 (GlobeNewswire)
May-30-24 08:00AM	Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire)
May-23-24 05:05PM	Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting (GlobeNewswire) -7.96% +8.80%
May-17-24 04:12PM	Google DeepMind CEO: 'This Is the Next $100 Billion AI Business' (InvestorPlace) +7.89%
May-09-24 08:00AM	Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-07-24 01:52PM	CRBP Stock Earnings: Corbus Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
08:17AM	Corbus Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-06-24 02:06PM	How the Medical Industry Could Produce the Biggest AI Stock Winners (InvestorPlace)
May-01-24 08:00AM	Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum (GlobeNewswire)
Apr-24-24 04:05PM	Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting (GlobeNewswire) -5.83% -5.74%
Apr-19-24 02:30PM	These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher? (InvestorPlace) +7.42%
Apr-16-24 08:50AM	Here's What Could Help Corbus Pharmaceuticals (CRBP) Maintain Its Recent Price Strength (Zacks)
Apr-12-24 06:40AM	7 A-Rated Aggressive Biotech Stocks to Bet On in 2024 (InvestorPlace)
Apr-02-24 08:00AM	Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (GlobeNewswire)
Mar-15-24 08:50AM	What Makes Corbus Pharmaceuticals (CRBP) a Good Fit for 'Trend Investing' (Zacks)
Mar-14-24 09:38AM	12 Most Profitable Biotech Stocks To Invest In (Insider Monkey)
Mar-12-24 08:21AM	Corbus Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance) +16.46%
08:00AM	Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-06-24 08:00AM	Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit (GlobeNewswire)
Feb-28-24 08:00AM	Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer (GlobeNewswire) +7.40%
Feb-06-24 09:50AM	Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-02-24 04:01PM	Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-31-24 09:19AM	Corbus Pharmaceuticals Announces Pricing of Public Offering (GlobeNewswire) +5.29%

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cohen Yuval	Chief Executive Officer	Oct 24 '25	Option Exercise	4.26	18,660	79,492	156,847	Oct 27 04:23 PM
Cohen Yuval	Chief Executive Officer	Oct 27 '25	Option Exercise	4.26	8,973	38,225	147,160	Oct 27 04:23 PM
Cohen Yuval	Chief Executive Officer	Oct 24 '25	Sale	17.01	18,660	317,407	138,187	Oct 27 04:23 PM
Cohen Yuval	Chief Executive Officer	Oct 27 '25	Sale	17.14	8,973	153,797	138,187	Oct 27 04:23 PM
Moran Sean F.	Chief Financial Officer	Oct 24 '25	Option Exercise	4.26	12,981	55,299	86,294	Oct 27 04:22 PM
Moran Sean F.	Chief Financial Officer	Oct 24 '25	Sale	17.02	12,981	220,937	73,313	Oct 27 04:22 PM
Cohen Yuval	Officer	Oct 24 '25	Proposed Sale	17.01	27,633	469,977		Oct 24 04:18 PM
Moran Sean F.	Officer	Oct 24 '25	Proposed Sale	17.02	12,981	220,922		Oct 24 04:14 PM
Altmeyer Anne	Director	Oct 20 '25	Option Exercise	4.80	1,060	5,088	7,251	Oct 21 04:54 PM
Altmeyer Anne	Director	Oct 20 '25	Sale	20.50	1,060	21,730	6,191	Oct 21 04:54 PM
Jenkins John Kenneth	Director	May 30 '25	Sale	7.35	2,783	20,465	33	Jun 02 04:30 PM
Altmeyer Anne	Director	May 30 '25	Sale	7.25	1,392	10,096	1,391	Jun 02 04:30 PM
Smethurst Dominic	Chief Medical Officer	Mar 06 '25	Sale	6.78	6,393	43,330	70,807	Mar 07 04:30 PM
Smethurst Dominic	Officer	Mar 06 '25	Proposed Sale	6.84	6,393	43,728		Mar 06 04:03 PM
Moran Sean F.	Chief Financial Officer	Feb 14 '25	Sale	8.76	2,792	24,446	73,313	Feb 18 05:40 PM
Cohen Yuval	Chief Executive Officer	Feb 14 '25	Sale	8.76	7,134	62,465	138,187	Feb 18 05:40 PM
Moran Sean F.	Officer	Feb 14 '25	Proposed Sale	9.48	2,792	26,468		Feb 14 04:18 PM
Cohen Yuval	Officer	Feb 14 '25	Proposed Sale	9.48	7,134	67,630		Feb 14 04:16 PM

Open in Screener

IMRX

Immuneering Corp

Dec 11 • 04:00PM ET

6.20

+0.04 0.65 %

Healthcare • Biotechnology • USA • NASD

Peers: RCKT SRRK RNA SYRS STRO CUE MGTX CABA UBX ADAP

| Held by: VTI VXF IWC DFAC AVSC CHNA

Index	-	P/E	-	EPS (ttm)	-1.78	Insider Own	26.02%	Shs Outstand	63.48M	Perf Week	-7.32%
Market Cap	400.33M	Forward P/E	-	EPS next Y	-1.60	Insider Trans	0.90%	Shs Float	47.77M	Perf Month	-8.01%
Enterprise Value	176.69M	PEG	-	EPS next Q	-0.31	Inst Own	41.88%	Short Float	15.26%	Perf Quarter	-26.97%
Income	-62.50M	P/S	-	EPS this Y	30.56%	Inst Trans	72.53%	Short Ratio	3.90	Perf Half Y	216.33%
Sales	0.00M	P/B	1.73	EPS next Y	-12.71%	ROA	-40.37%	Short Interest	7.29M	Perf YTD	181.82%
Book/sh	3.59	P/C	1.76	EPS next 5Y	8.55%	ROE	-43.75%	52W High	10.08 -38.49%	Perf Year	189.72%
Cash/sh	3.52	P/FCF	-	EPS past 3/5Y	-16.91% -46.45%	ROIC	-26.99%	52W Low	1.10 463.64%	Perf 3Y	9.35%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.06% 7.63%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	9.32%	Oper. Margin	-	ATR (14)	0.48	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	24.00	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	40.57	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	24.00	EPS Q/Q	22.89%	SMA20	-9.59%	Beta	0.46	Target Price	16.83
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	-4.41%	Rel Volume	0.44	Prev Close	6.16
Employees	66	LT Debt/Eq	0.02	Earnings	Nov 12 AMC	SMA200	53.87%	Avg Volume	1.87M	Price	6.20
IPO	Jul 30, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.14% -	Trades		Volume	822,531	Change	0.65%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-31-25	Initiated	Leerink Partners	Outperform	$15
Dec-13-24	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Mar-15-24	Reiterated	Needham	Buy	$20 → $15
Mar-15-24	Downgrade	TD Cowen	Outperform → Market Perform
Mar-15-24	Downgrade	Jefferies	Buy → Hold	$16 → $3
Dec-01-23	Initiated	Needham	Buy	$20
Jun-26-23	Resumed	Oppenheimer	Outperform	$25
Apr-19-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$5 → $14
Apr-19-23	Upgrade	Mizuho	Neutral → Buy	$10 → $20
Mar-30-23	Initiated	Mizuho	Neutral	$10
Feb-03-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$12 → $5
Jul-08-22	Initiated	Chardan Capital Markets	Buy	$18
Apr-01-22	Initiated	Oppenheimer	Outperform	$25
Jan-07-22	Initiated	Piper Sandler	Overweight	$41

Show Previous Ratings

Nov-26-25 12:00PM	Immuneering (IMRX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:55AM	Wall Street Analysts See a 126.21% Upside in Immuneering (IMRX): Can the Stock Really Move This High? (Zacks)
Nov-25-25 08:00AM	Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-12-25 04:05PM	Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates (GlobeNewswire)
Nov-10-25 11:21AM	Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates? (Zacks)
04:05PM	Loading…
Nov-04-25 04:05PM	Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025 (GlobeNewswire)
Oct-31-25 09:33AM	Apple upgraded, Comcast downgraded: Wall Street's top analyst calls (The Fly) +7.18%
Sep-30-25 11:42AM	Positive Trial Data Supports 43% Upside for Immuneering Corporation (IMRX) (Insider Monkey)
Sep-26-25 04:01PM	Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 (GlobeNewswire) -16.46%
Sep-25-25 12:08AM	Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi (GlobeNewswire) -13.33%
Sep-24-25 04:05PM	Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi (GlobeNewswire) +7.45%
04:01PM	Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP (GlobeNewswire)
Sep-16-25 07:00AM	Immuneering Appoints Dr. Thomas Schall as Chairman of the Board (GlobeNewswire) +5.73%
Sep-10-25 07:00AM	Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25 (GlobeNewswire) +15.46%
Aug-26-25 04:05PM	Immuneering Announces Closing of $25 Million Private Placement (GlobeNewswire) -12.33%
11:17AM	Loading…
11:17AM	Immuneering Stock Rises 21.7% on Supply Agreement With LLY (Zacks)
Aug-25-25 08:00AM	Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib (GlobeNewswire) +21.68%
Aug-21-25 08:00AM	Immuneering Announces $25 Million Private Placement (GlobeNewswire) +34.99%
Aug-13-25 04:05PM	Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) -5.59%
Jul-10-25 09:20AM	Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up (PR Newswire)
Jul-09-25 08:00AM	Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib (GlobeNewswire) +11.25%
Jul-08-25 04:00AM	The MEK effect on cancer a slow and steady approach to drug resistance (Pharma Voice)
Jun-20-25 09:21AM	With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology (PR Newswire) -7.58%
Jun-17-25 06:00AM	Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients (GlobeNewswire) -23.21%
Jun-16-25 08:00AM	Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 (GlobeNewswire) +24.74%
May-29-25 08:00AM	Immuneering to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) -5.83%
May-05-25 04:05PM	Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-02-25 08:00AM	Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-21-25 04:30PM	Immuneering Corporation Announces Grant of Inducement Award (GlobeNewswire) +9.09%
Mar-20-25 04:05PM	Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
07:12AM	Loading…
07:12AM	Immuneering names Igor Matushansky as chief medical officer (SeekingAlpha)
07:00AM	Immuneering Names Dr. Igor Matushansky as Chief Medical Officer (GlobeNewswire)
Feb-06-25 07:00AM	Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo (cemiplimab) (GlobeNewswire)
Feb-03-25 04:05PM	Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-13-25 08:00AM	Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer (GlobeNewswire)
Jan-07-25 09:28AM	Why Is Immuneering Stock Trading Higher On Tuesday? (Benzinga)
07:00AM	Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms (GlobeNewswire)
Dec-23-24 10:49AM	How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options (PR Newswire) +10.00%
Dec-19-24 08:00AM	Immuneering Launches Pancreatic Cancer Advisory Board (GlobeNewswire) +13.58%
Dec-17-24 08:00AM	Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025 (GlobeNewswire)
Dec-13-24 02:10PM	Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? (Benzinga) -17.01%
Dec-12-24 08:00AM	Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma (GlobeNewswire) -7.94%
Nov-27-24 08:00AM	Immuneering to Present at the Piper Sandler 36 Annual Healthcare Conference (GlobeNewswire)
Nov-13-24 04:05PM	Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -6.56% +13.45%
Oct-15-24 08:00AM	Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer (GlobeNewswire) +15.50%
Sep-13-24 08:14AM	Why Is Nanocap Immuneering Stock Trading Higher On Friday? (Benzinga) +41.26%
Sep-12-24 04:05PM	Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients (GlobeNewswire) +10.85%
Aug-29-24 08:00AM	Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-06-24 04:05PM	Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -8.06%
Jul-31-24 04:05PM	Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer (GlobeNewswire) +19.47%
May-29-24 04:05PM	Immuneering to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-17-24 12:50PM	Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment (PR Newswire)
May-07-24 10:55PM	IMRX Stock Earnings: Immuneering Misses EPS for Q1 2024 (InvestorPlace) -5.45%
04:05PM	Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
May-06-24 04:30PM	Immuneering Recognizes Melanoma Awareness Month (GlobeNewswire)
Apr-09-24 12:00PM	IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models (GlobeNewswire)
Apr-03-24 04:05PM	Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-27-24 08:00AM	Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations (GlobeNewswire)
Mar-18-24 11:02AM	Immuneering (IMRX) Plummets 71% in One Week: Here's Why (Zacks) +34.03%
Mar-14-24 07:00AM	Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors (GlobeNewswire) -50.68%
Mar-12-24 08:00AM	Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors (GlobeNewswire)
Mar-11-24 08:00AM	Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors (GlobeNewswire) -9.53%
Mar-06-24 08:00AM	Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning (Newsfile)
Mar-05-24 05:00PM	Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-04-24 08:00AM	Immuneering to Participate in the Cowen 44th Annual Health Care Conference (GlobeNewswire)
Mar-03-24 07:01PM	Immuneering Corp (IMRX) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
Mar-01-24 08:00AM	Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-20-24 08:00AM	Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer (GlobeNewswire)
Feb-14-24 03:45PM	3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave (InvestorPlace) +8.00%
Feb-01-24 08:00AM	Immuneering Announces Participation in February Investor Conferences (GlobeNewswire)
Dec-12-23 08:00AM	Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations (GlobeNewswire) -7.11%
Nov-20-23 04:05PM	Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +25.45%
Nov-09-23 04:05PM	Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) -11.86%
Oct-12-23 04:05PM	Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference (GlobeNewswire) -6.65%
Oct-04-23 04:05PM	Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-06-23 08:00AM	Immuneering to Present at the Morgan Stanley Healthcare Conference (GlobeNewswire)
Aug-03-23 04:05PM	Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-02-23 06:09AM	Immuneering Corporation (NASDAQ:IMRX) insiders have significant skin in the game with 28% ownership (Simply Wall St.)
Jul-05-23 09:55AM	Wall Street Analysts Think Immuneering Corporation (IMRX) Could Surge 103.8%: Read This Before Placing a Bet (Zacks)
Jun-05-23 08:00AM	Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors (GlobeNewswire)
May-30-23 08:00AM	Immuneering to Present at the Jefferies Healthcare Conference (GlobeNewswire) +6.86%
May-04-23 07:25PM	Immuneering Corporation (IMRX) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -8.75%
04:05PM	Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-18-23 09:24AM	Immuneering Announces $30 Million Underwritten Offering (GlobeNewswire) +9.60%
09:00AM	Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline (GlobeNewswire)
04:20AM	Morphic Holding, Inc. (MORF) Moves 22.5% Higher: Will This Strength Last? (Zacks)
Apr-12-23 04:05PM	Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-11-23 03:56AM	Immuneering Corporation (IMRX) Surges 18.5%: Is This an Indication of Further Gains? (Zacks) +5.78%
Apr-05-23 08:00AM	Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire)
Mar-28-23 08:00AM	Immuneering Appoints Harold E. Brakewood as Chief Business Officer (GlobeNewswire) -7.40%
Mar-27-23 09:55AM	Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 102.51%: Here's is How to Trade (Zacks)
Mar-24-23 01:25PM	Why Shares of Immuneering Jumped This Week (Motley Fool)
Mar-23-23 06:18AM	Immuneering Corporation (IMRX) Soars 16.9%: Is Further Upside Left in the Stock? (Zacks)
Mar-14-23 04:30PM	Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire) +5.62% -8.05%
Mar-09-23 09:55AM	Does Immuneering Corporation (IMRX) Have the Potential to Rally 210.19% as Wall Street Analysts Expect? (Zacks) +5.47%
Mar-08-23 07:14AM	Immuneering Corporation (NASDAQ:IMRX) Q4 2022 Earnings Call Transcript (Insider Monkey) +22.87%
Mar-06-23 05:45PM	Immuneering Corporation (IMRX) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +6.17%
04:05PM	Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-05-23 06:30PM	Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity (GlobeNewswire)
Feb-28-23 08:00AM	Immuneering Announces Participation in March Investor Conferences (GlobeNewswire)

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Feinberg Peter	Director	Oct 03 '25	Buy	6.67	7,500	50,025	156,766	Oct 07 08:56 AM
Morales Mallory	Chief Accounting Officer	Oct 01 '25	Buy	6.39	300	1,917	27,533	Oct 02 09:02 AM
Neufeld Leah R	CHIEF PEOPLE OFFICER	Oct 01 '25	Buy	6.38	800	5,103	23,344	Oct 02 08:57 AM
Bookman Michael	CHIEF LEGAL OFFICER, SECRETARY	Oct 01 '25	Buy	6.83	1,020	6,966	4,870	Oct 02 08:52 AM
Feinberg Peter	Director	Sep 30 '25	Buy	7.03	7,500	52,730	149,266	Oct 01 08:59 AM
Feinberg Peter	Director	Sep 29 '25	Buy	7.18	5,000	35,900	141,766	Sep 30 09:00 AM
BERMAN ANN E	Director	Sep 23 '25	Proposed Sale	9.72	14,000	136,080		Sep 23 08:48 AM
HAUSMAN DIANA	Director	Jul 02 '25	Buy	3.62	3,000	10,874	3,000	Jul 07 08:59 AM
HAUSMAN DIANA	Director	Jul 02 '25	Buy	3.60	2,500	8,989	2,500	Jul 07 08:59 AM
Neufeld Leah R	CHIEF PEOPLE OFFICER	Jul 02 '25	Buy	3.57	700	2,499	10,729	Jul 07 08:52 AM
Zeskind Benjamin J.	PRESIDENT AND CEO	Jul 02 '25	Buy	3.53	7,015	24,792	2,312,852	Jul 03 09:12 AM
Zeskind Benjamin J.	PRESIDENT AND CEO	Jul 01 '25	Buy	3.38	2,985	10,087	2,305,837	Jul 03 09:12 AM
Schall Thomas J.	Director	Jun 27 '25	Buy	3.66	9,500	34,788	52,885	Jun 30 09:09 AM
Hall Brett Matthew	CHIEF SCIENTIFIC OFFICER	Jun 20 '25	Buy	2.70	7,415	20,020	353,311	Jun 24 09:01 AM
Hall Brett Matthew	CHIEF SCIENTIFIC OFFICER	Jun 23 '25	Buy	2.43	6,007	14,596	359,318	Jun 24 09:01 AM
Brakewood Harold Eugene	Chief Business Officer	Jun 20 '25	Buy	2.53	1,900	4,804	5,800	Jun 24 08:52 AM
Feinberg Peter	Director	Jun 18 '25	Buy	2.53	25,000	63,188	136,766	Jun 23 09:09 AM
Zeskind Benjamin J.	PRESIDENT AND CEO	Jun 18 '25	Buy	2.39	21,000	50,144	2,302,852	Jun 20 09:09 AM
Schall Thomas J.	Director	Jun 17 '25	Buy	2.21	40,485	89,278	43,385	Jun 18 09:11 AM

EYPT

EyePoint Inc

OKUR

OnKure Therapeutics Inc

AARD

Aardvark Therapeutics Inc

DRUG

Bright Minds Biosciences Inc

BIOA

BioAge Labs Inc

CRBP

Corbus Pharmaceuticals Holdings Inc

IMRX

Immuneering Corp

Upgrade your FINVIZ experience